Pfizer, Trump and tariffs Bourla

Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's election victory.
Pfizer CEO says he's prepared to shift manufacturing to the U.S. amid tariff threats
CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if necessary, as the Trump administration considers imposing tariffs on pharmaceuticals.
Pfizer Prepared to Reshore Manufacturing if Trump Makes Good on Tariff Threats
Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing facilities across the U.S. in five years.
Pfizer could shift overseas production to US if Trump's pharma tariffs take hold, CEO says
As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if pharmaceut | Pfizer’s local manufacturing setup is already well positioned in the U.
Pfizer could use existing U.S. production to counter tariff hit, Reuters reports
Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous
Pfizer could use existing US manufacturing to counter potential tariff hit
Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens numerous tariffs on imported goods.
Pfizer may soon move its overseas manufacturing to United States to counter potential tariff hit
Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the United States. The plan comes as the Trump administration
Pfizer's Strategic Manufacturing Shift Amidst Tariff Threats
Pfizer CEO Albert Bourla announced the possibility of shifting overseas manufacturing to U.S. plants. This response is due to the Trump administration's tariff threats on imported goods. Bourla mentioned their U.
Pfizer could move outside manufacturing to the US, says CEO
(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the U.S., if required, as the Donald Trump administration threatens numerous tariffs on imported goods.
STAT2h
Pharmalittle: We’re reading about Pfizer navigating tariffs, Makary’s pledge to avoid conflicts, and more
Pfizer CEO Albert Bourla said the drugmaker might move overseas manufacturing to its plants in the U.S. as Trump threatens ...
Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's ...
Irish Independent on MSN22h
Pfizer says more drugs can be made in its US plants for domestic market, if needed
Pfizer CEO Albert Bourla said on Monday that the drugmaker can shift manufacturing for the US market to its existing plants in the US, as the threat of tariffs puts a question mark over global supply ...
STAT7dOpinion
Pfizer CEO Albert Bourla inflicts injury on his company — and all of pharma
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...